Our Board of Directors bring a wealth of experience and business acumen to their role ensuring MDI remains at the forefront of the field on the global stage.
Gordon has enjoyed a long and successful international business career. For over 30 years he was a key part of the internationalisation of the CSL Group, a global specialty biotechnology company that was established in Australia and grew to become Australia’s largest public company. Gordon held a range of business and functional leadership roles within CSL including Chief Financial Officer. At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world. In 2016 Seqirus was highly unprofitable with a turnover of circa $700m.
By 2019 the business generated circa $150m EBIT from a turnover of $1.2b.